BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment ofCertain Officers; Compensatory Arrangements of Certain Officers.
On December 21, 2018, the Board of Directors (the “Board”) of BioSig Technologies, Inc. (the “Company”) elected Jeffrey F. O’Donnell as Lead Director of the Company for a term of one (1) year, commencing January 1, 2019, or until his replacement is elected. For his services as Lead Director, Mr. O’Donnell will receive (i) cash compensation of $8,000 per month and (ii) 30,000 shares of restricted common stock of the Company, in addition to the compensation paid to Mr. O’Donnell as a member of the Board. The shares of common stock awarded to Mr. O’Donnell will all vest on January 1, 2020. Mr. O’Donnell currently is a member of the Audit Committee and the Compensation Committee of the Board, has been a Director of the Company since February 2015 and had previously served as a Director of the Company from October 2011 until February 2014.
About BioSig Technologies, Inc. (OTCMKTS:BSGM)
BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.
